The compatibility between packing material and ipratropium bromide aerosol.
- Author:
Zhi-hua YUE
1
;
Dian-dian SHEN
;
Chang-qin HU
Author Information
1. National Institute for the Control of Pharmaceutical and Biological Products, Beijing 100050, China.
- Publication Type:Journal Article
- MeSH:
Aerosols;
Antioxidants;
analysis;
Bronchodilator Agents;
administration & dosage;
chemistry;
Butylated Hydroxytoluene;
analysis;
Chromatography, High Pressure Liquid;
Drug Incompatibility;
Drug Packaging;
Ipratropium;
administration & dosage;
chemistry;
Quality Control;
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
- From:
Acta Pharmaceutica Sinica
2010;45(8):1035-1038
- CountryChina
- Language:Chinese
-
Abstract:
With the establishment of HPLC and LC-MS methods to determine the related substances and the content of active pharmaceutical ingredient (API) in ipratropium bromide aerosol products, several packing material-related impurities were identified, including antioxygen BHT and antioxygen 2246. Results showed that these leachable additives from the packing materials may present at a relative high level in the drug solution, and the low content of API in the drug products is usually due to the adsorption of the packing material as well as the leaking of contents. The current available assay methods for the control of ipratropium bromide aerosol products are often lack of specificity and unable to assure the drug quality effectively. To meet the increasing attention on the regulations of drug packing materials, our research would be a pilot study, indicating that the inappropriate packing materials could cause the migration and adsorption of the active ingredients, and the importance to have compatibility studies between packing materials and drugs.
